These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 4044011)

  • 1. Decreased natural killer cell activity after prolonged administration of interferon in cancer patients.
    Bravo Cuellar A; Martin Ruiz JL; Orbach-Arbouys S
    Immunol Lett; 1985; 10(3-4):137-9. PubMed ID: 4044011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cimetidine enhances interferon induced augmentation of NK cell activity and suppresses interferon production.
    Hirai N; Hill NO; Motoo Y; Osther K
    Acta Pathol Microbiol Immunol Scand C; 1985 Aug; 93(4):153-9. PubMed ID: 4050442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer cell response to interferons.
    Abbud-Filho M; Ransil BJ; Kelley VE; Fiers W; Strom TB
    Clin Immunol Immunopathol; 1986 May; 39(2):264-76. PubMed ID: 3084143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergism between alpha-interferon and interleukin-2-activated killer cells: in vitro studies.
    Di Raimondo F; LaPushin R; Hersh EM
    Acta Haematol; 1987; 78 Suppl 1():77-83. PubMed ID: 3124452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro modulation of human natural killer cell activity by interferon: generation of adherent suppressor cells.
    Uchida A; Yanagawa E; Kokoschka EM; Micksche M; Koren HS
    Br J Cancer; 1984 Oct; 50(4):483-92. PubMed ID: 6237664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon.
    Lotzová E; Savary CA; Quesada JR; Gutterman JU; Hersh EM
    J Natl Cancer Inst; 1983 Nov; 71(5):903-10. PubMed ID: 6580490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological effects of recombinant interferon alfa-2a in patients with disseminated melanoma.
    Hersey P; MacDonald M; Hall C; Spurling A; Edwards A; Coates A; McCarthy W
    Cancer; 1986 Apr; 57(8 Suppl):1666-74. PubMed ID: 3485011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer cell activity against cultured melanoma cells: a dye-reduction technique with studies on augmented activity by interferon subtypes.
    Losinno C; Wines BD; Johns TG; Mackay IR
    Nat Immun; 1992; 11(4):215-24. PubMed ID: 1384830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer cell activity in multiple sclerosis patients treated with recombinant interferon-alpha 2.
    Hirsch RL; Johnson KP
    Clin Immunol Immunopathol; 1985 Nov; 37(2):236-44. PubMed ID: 3899434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired alpha-interferon production and natural killer activity in blood mononuclear cells in myelodysplastic syndromes.
    Okabe M; Minagawa T; Nakane A; Sakurada K; Miyazaki T
    Scand J Haematol; 1986 Aug; 37(2):111-7. PubMed ID: 3489981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parameters of interferon action: I. Immunological effects of whole cell leukocyte interferon (IFN-alpha) in phase I-II trials.
    Ernstoff MS; Fusi S; Kirkwood JM
    J Biol Response Mod; 1983; 2(6):528-39. PubMed ID: 6363630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of intravascular mouse melanoma dissemination by recombinant human interferon alpha A/D.
    Yokoyama T; Yoshie O; Aso H; Ebina T; Ishida N
    Jpn J Cancer Res; 1986 Jan; 77(1):80-4. PubMed ID: 3082819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous and allogenic natural cell mediated cytotoxicity at the single cell level: divergent effects of interferons and interleukin 2 on binding and lysis.
    Klappacher G
    Cancer Lett; 1989 Sep; 47(1-2):69-77. PubMed ID: 2636034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
    Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
    Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A study of effective administration of recombinant interferon-gamma in renal cell carcinoma regarding immunological influence on peripheral blood lymphocytes].
    Kawata N; Ono M; Kodama M; Yamanaka Y; Hirakata H; Hirano D; Fuse T; Takimoto Y
    Hinyokika Kiyo; 1995 Jan; 41(1):21-6. PubMed ID: 7900565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones.
    van de Griend RJ; Ronteltap CP; Gravekamp C; Monnikendam D; Bolhuis RL
    J Immunol; 1986 Mar; 136(5):1700-7. PubMed ID: 3005399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant interferons or interleukin-2 increase cytotoxicity by human monocytes and NK cells.
    Frey JR; Kamber M; Peck R
    Lymphokine Res; 1987; 6(3):215-27. PubMed ID: 3114569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The beneficial effects of alpha-interferon in hairy cell leukemia are not attributable to NK cell-mediated cytotoxicity.
    Griffiths SD; Cawley JC
    Leukemia; 1987 Apr; 1(4):372-6. PubMed ID: 3669763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma.
    Blanchard DK; Djeu JY
    J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant interferon alpha 2 stimulation of target-binding by natural killer cells.
    Heidemann E; Weber J; Schmidt H; Reichmann U
    Klin Wochenschr; 1986 Oct; 64(20):1036-40. PubMed ID: 3465970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.